Innovative research performed by Dr. Michael Rützler together with  Søren Nielsen, MD, and Prof. Per Kjellbom from Lund University have led to the concept that inhibitors of aquaporins have potential to being developed into a therapy for reducing the high blood levels of glucose in diabetes patients.

Based on this research and initial performed drug discovery program resulting in potent and selective small molecule inhibitors, Apoglyx will focus on the preclinical development and the commercialization of patented Aquaporin technology.